共 237 条
[1]
Siegel RL(2019)Cancer statistics, 2019 CA Cancer J Clin 69 7-34
[2]
Miller KD(2017)BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer Oncogene. 36 6235-6243
[3]
Jemal A(2019)Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) Lung Cancer 137 113-122
[4]
Wang J(2010)De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer J Thorac Oncol 5 399-400
[5]
Jia Y(2016)Acquired METD1228V mutation and resistance to MET inhibition in lung Cancer Cancer Discov 6 1334-1341
[6]
Zhao S(2020)Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2 Pharmacol Res 159 105007-200
[7]
Zhang X(2018)Induction of apoptosis by morusin in human non-small cell lung cancer cells by suppression of EGFR/STAT3 activation Biochem Biophys Res Commun 505 194-5757
[8]
Wang X(2020)Torin2 inhibits the EGFR-TKI resistant non-small lung Cancer cell proliferation through negative feedback regulation of Akt/mTOR signaling J Cancer 11 5746-208
[9]
Han X(2019)The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens J Exp Clin Cancer Res 38 282-86
[10]
Gelatti ACZ(2005)EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer N Engl J Med 353 207-369